目的 探究二十五味松石丸聯(lián)合恩替卡韋治療慢性乙型肝炎的有效性。方法 選取邯鄲市第一醫(yī)院2010年9月—2017年9月收治慢性乙型肝炎患者的84例，隨機(jī)分成對(duì)照組和治療組，每組各42例。對(duì)照組口服恩替卡韋片，1片/次，1次/d；治療組患者在對(duì)照組基礎(chǔ)上開(kāi)水泡服二十五味松石丸，1丸/次，1次/d。兩組患者均連續(xù)治療3個(gè)月。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者HBV-DNA轉(zhuǎn)陰率、谷丙轉(zhuǎn)氨酶（ALT）復(fù)常率和持續(xù)應(yīng)答率及血清生化指標(biāo)和不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組臨床有效率為78.57%，顯著低于治療組的95.24%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組患者HBV-DNA轉(zhuǎn)陰率、ALT復(fù)常率及持續(xù)應(yīng)答率均要顯著高于對(duì)照組患者，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者轉(zhuǎn)化生長(zhǎng)因子β1（TGF-β1）、透明質(zhì)酸（HA）和Ⅳ型膠原（Ⅳ-C）血清水平均顯著降低（P<0.05），且治療組患者這些血清生化指標(biāo)明顯低于對(duì)照組（P<0.05）。治療期間，治療組藥物不良反應(yīng)發(fā)生率為4.76%，顯著低于對(duì)照組的11.90%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 二十五味松石丸聯(lián)合恩替卡韋治療慢性乙型肝炎臨床效果好，安全性高，同時(shí)可減慢肝纖維化進(jìn)程，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Ershiwuwei Songshi Pills combined with entecavir in treatment of chronic hepatitis B. Methods Patients (84 cases) with chronic hepatitis B in Handan First Hospital from September 2010 to September 2017 were randomly divided into control and treatment groups, and each group had 42 cases. Patients in the control group were po administered with Entecavir Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Ershiwuwei Songshi Pills on the basis of the control group, 1 pill/time, once daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the HBV-DNA negative rate, ALT recurrence rate and sustained response rate, serum biochemical indexes and adverse reaction in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 78.57%, which was significantly lower than 95.24% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the HBV-DNA negative rate, ALT recurrence rate, and sustained response rate in the treatment group was significantly higher than that in the control group, with significant difference between two groups (P<0.05). After treatment, the serum TGF-β1, HA, and Ⅳ-C levels in two groups were significantly decreased (P<0.05), and the serum biochemical indexes levels in the treatment group were significantly lower than that in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 4.76%, which was significantly lower than 11.90% in the control group, with significant difference between two groups (P<0.05). Conclusion Ershiwuwei Songshi Pills combined with entecavir has good clinical efficacy in treatment of chronic hepatitis B with high safety, and can slow down the process of liver fibrosis, which has a certain clinical application value.